Evidence map›Paper›PMID 41644738›Full record

ArticleActa pharmacologica Sinica2026

Asiatic acid promotes CD8

Yu-Chuan Chen, Xue-Lian Gao, Ge Zeng, Kai-Kai Zhang, Chang Yuan, Chang-Hao Cheng, Jia-Yuan Wan, He-Qi Zhou, Zhi-Xian Lan, De-Kai Zheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yu-Chuan Chen *Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Xue-Lian Gao *Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Ge Zeng *Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Kai-Kai ZhangKey Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Chang YuanKey Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Chang-Hao ChengKey Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Jia-Yuan WanKey Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
He-Qi ZhouDepartment of Critical Care, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Zhi-Xian LanKey Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
De-Kai ZhengKey Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Qiu-Hong YouKey Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Jian SunKey Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. sunjian@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has shown limited efficacy in hepatocellular carcinoma (HCC) due to the immunosuppressive tumor microenvironment (TME). Previous studies show that asiatic acid (AA), a naturally occurring pentacyclic triterpenoid, exhibits potent inhibitory effects on tumor cell proliferation. In this study we investigated the effects of AA on the TME and immunotherapy in HCC. Both subcutaneous and orthotopic HCC models were established in male mice. The mice were treated with AA (50 mg·kg⁻¹·d⁻¹, i.g) for two weeks. At the experimental endpoint, mice were euthanized, and tumor-infiltrating immune cell populations were analyzed using flow cytometry. We showed that AA treatment effectively converted "cold tumors" into "hot tumors" by promoting CD8

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularCD8-Positive T-LymphocytesChemokine CXCL10Histone DeacetylasesLiver NeoplasmsPentacyclic TriterpenesRepressor ProteinsAnimalsCell Line, TumorHistone Deacetylase InhibitorsHumansMaleMiceMice, Inbred C57BLTumor MicroenvironmentAntineoplastic Agentsasiatic acidChemokine CXCL10Cxcl10 protein, mouseHDAC8 protein, humanHistone Deacetylase InhibitorsHistone DeacetylasesPentacyclic TriterpenesRepressor Proteinsasiatic acidCD8+ T cellCXCL10HDAC8hepatocellular carcinomatumor microenvironment

Identifiers

PMID41644738
PMCPMC13197474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.